Results 51 to 60 of about 908,554 (203)

Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.

Archives of Pathology & Laboratory Medicine, 2023
CONTEXT.— The neurotrophic tropomyosin receptor kinase (NTRK) family gene rearrangements have been recently incorporated as predictive biomarkers in a "tumor-agnostic" manner. However, the identification of these patients is extremely challenging because
S. Hernandez, E. Conde, Aida Molero, A. Suárez-Gauthier, R. Martínez, M. Alonso, C. Plaza, C. Camacho, Debora Chantada, Laura Juaneda-Magdalena, Enrique Garcia-Toro, P. Saiz-Lopez, F. Rojo, M. Abad, V. Boni, S. del Carmen, R. M. Regojo, M. Sánchez-Frías, C. Teixidó, L. Paz-Ares, F. López-Rios   +20 more
semanticscholar   +1 more source

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

Cancer Medicine, 2022
TRK fusions are rare but targetable mutations which occur across a wide variety of cancer types. We report the prevalence of approximately 0.7% for NTRK‐positive colorectal cancer (CRC) by genetically profiling 2519 colonic and rectal tumors.
Hui Wang, Zhi‐Wei Li, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Sai‐Hong Ignatius Ou, Yu Yang   +7 more
doaj   +1 more source

MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas

Frontiers in Oncology, 2021
To gain insight into the clinicopathologic profile of colorectal carcinomas harboring oncogenic NTRK fusions based on eastern populations as well as make the best testing algorithm for the screen, we use pan-Trk immunohistochemistry (IHC), fluorescence ...
Yao Fu, Zheng Li, Fuping Gao, Jun Yang, Hongyan Wu, Biao Zhang, Xiaohong Pu, Xiangshan Fan   +7 more
doaj   +1 more source

Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.

PLoS ONE, 2022
The clinical profiles and outcomes of patients with neurotrophic tropomyosin receptor kinase fusion-positive (NTRK+) solid tumors receiving standard of care other than tropomyosin receptor kinase inhibitor (TRKi) targeted therapy have not been well ...
Derrek P Hibar, George D Demetri, Solange Peters, Jessica Davies, Olivier Humblet, Sophia L Maund, Laura Perez   +6 more
doaj   +1 more source

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions

Frontiers in Oncology, 2022
The fusions of receptor tyrosine kinase (RTK) involving anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and neurotrophic receptor tyrosine kinase (NTRK) represent the potential targets of therapeutic intervention for various types of solid ...
Yinghuan Dai, Ping Liu, Wenlong He, Lizhen Yang, Yang Ni, Yang Ni, Xuejiao Ma, Xuejiao Ma, Furong Du, Furong Du, Chao Song, Chao Song, Yang Liu, Yi Sun   +13 more
doaj   +1 more source

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population

The Journal of Pathology: Clinical Research, 2021
The molecular profile of neurotrophic tyrosine kinase receptor (NTRK) gene fusions in lung adenocarcinoma (LUAD) is not fully understood. Next‐generation sequencing (NGS) and pan‐tyrosine kinase receptor (TRK) immunohistochemistry (IHC) are powerful ...
Ruiying Zhao, Feng Yao, Chan Xiang, Jikai Zhao, Zhanxian Shang, Lianying Guo, Wenjie Ding, Shengji Ma, Anbo Yu, Jinchen Shao, Lei Zhu, Yuchen Han   +11 more
doaj   +1 more source

NTRK fusion-positive cancers and TRK inhibitor therapy [PDF]

Nature Reviews Clinical Oncology, 2018
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the clinic using a variety of methods, including tumour DNA and RNA sequencing and plasma cell-free DNA profiling.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon   +2 more
openaire   +2 more sources

Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]

, 2018
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma, Florento, Elena, Gatalica, Zoran, Palazzo, Juan, Sanati, Souzan, Swensen, Jeffrey, Vranic, Semir, Xiu, Joanne   +7 more
core   +2 more sources

Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers [PDF]

, 2022
Gene fusions can act as oncogenic drivers and offer targets for cancer therapy. Since fusions are rare in colorectal cancer (CRC), their universal screening seems impractical.
Haglund, Caj, Kairisto, Veli, Kallajoki, Markku, Kero, Mia, Kytölä, Soili, Nummela, Pirjo, Peltomäki, Päivi, Ristimäki, Ari, Tammio, Hanna, Tuominen, Jenni, Ukkola, Iiris   +10 more
core   +1 more source

TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks [PDF]

, 2021
not ...
Brandi G., Rizzo A.
core   +1 more source